Abstract
When the radioimmunoassay for insulin was developed, it became apparent that serum contained far more insulin-like biologic activity than could be accounted for simply by its content of immunoreactive insulin (1). This insulin-like activity was initially termed by Froesch et al. nonsuppressible insulin-like activity (NSILA) (2). Later, the term somatomedin was introduced to denote the uncharacterized factor that displayed insulin-like activity and mediated the action of GH in the stimulation of somatic growth (3). Further studies of Froesch and colleagues demonstrated that somatomedin C exerted metabolic effects in vitro that closely resembled those of insulin (4-9); hence, its redesignation as insulin-like growth factor I (IGF-I).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sara V, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990;70:591–614.
Froesch ER, Burgi H, Ramseirer EB, Bally P, Labhart. Antibody supressible and non-suppressible insulin-like activities in human serum and their physiological significance. J Clin Invest 1963;42:1816–34.
Daughday WK, Hall K, Raben MS, Salmon WD Jr, Van den Brande JL, Van Wyk JJ. Somatomedin: proposed designation for sulphation factor. Nature 1972;235:107.
Meuli C, Froesch ER. Insulin and non suppressible insulin-like activity (NSILAs) stimulated the same glucose transport system via two separate receptors in rat heart. Biochem Biophys Res Commun 1977;75:689–95.
Zapf J, Schoenle E, Froesch ER. Insulin-like growth factors I and II, some biological actions and receptor binding characteristics of two purified constituents of non suppressible insulin-like activity of human serum. Eur J Biochem 1978;87:265–96.
Poggi C, Le Marchand-Brustel Y, Zapf J, Froesch ER, Freychet P. Effects of binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: comparison with insulin. Endocrinology 1979;104:723–30.
Zapf J, Froesch ER, Humbel RE. The insulin-like growth factors (GF) of human serum: chemical and biological characterization and aspects of their possible physiological role. Curr Top Cell Regul 1981;19:257–309.
Rechler MM, Nissley SP, King GL, et al. Multiplication stimulating activity (SA) from BRL3A rat liver line: relaxation to human somatomedins and insulin. J Supramol Struct Cell Biochem 1981;15:253–86.
Guenther HL, Guenther HE, Froesch ER, Fleisch H. Effects of insulin-like growth factor on collagen and glycosaminoglycan synthesis by rabbit articular chondrocytes in culture. Experientia 1982;38:979–80.
Zapf J, Hauri C, Waldvogel M, Froesch ER. Acute metabolic effects and half-lives of intravenously administered insulin-like growth factors I and II in normal and hypophosectomized rats. J Clin Invest 1986;77:1768–75.
Guller HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987;317: 137–40.
Ross RJM, Miell JP, Buchanan CR. Avoiding autocannibalism. Br Med J 1991;303:1147–8.
Froesch ER, Guler HP, Schmid C, Binz K, Zapf J. Therapeutic potential of insulin like growth factor 1. Trends Endocrinol Metab 1990;1:254–60.
Amiel SA, Sherwin RS, Hintz RL, Gertner JM, Press CM, Tamborlane WV. Effect of diabetes and its control on insulin-like growth factors in the young subjects with type I diabetes. Diabetes 1984;33:1175–9.
Tan K, Baxter RE. Serum insulin-like growth factor I levels in adult diabetic patients: the effect of age. J Clin Endocrinol Metab 1986;63:651–5.
Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors: studies in diabetics with and without retinopathy. N Engl J Med 1983;304:527–30.
Amer P, Sjoberg M, Gjotterberg M, Skottner A. Circulating insulin-like growth factor I in type I diabetic patients with retinopathy. Diabetologia 1989;32:753–8.
Unterman TG, Patel K, Kumar Mahathre V, Rajamohan G, Oehler DT, Becker RE. Regulation of low molecular weight insulin-like growth factor binding proteins in experimental diabetes mellitus. Endocrinology 1990;126: 2614–24.
Holly JMP, Biddlecombe RA, Dunger DB, et al. Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin: a new role for insulin? Clin Endocrinol (Oxf) 1988;29:667–75.
Tamborlane WV, Hintz RL, Bergman M, Genel M, Felig P, Sherwin RS. Insulin infusion pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. N Engl J Med 1981;305:303–7.
Press M, Tamborlane WV, Sherwin RS. Importance of raised growth hormone lends in mediating the metabolic derangements of diabetes. N Engl J Med 1984;310:810–5.
Jacob RJ, Sherwin RS, Bowen L, et al. Metabolic effects of IGF-1 and insulin in spontaneously diabetic BB/w rats. Am J Physiol 1991;260:E262–8.
Synder DK, Clemmon DR. Insulin-dependent regulation of insulin-like growth factor-binding protein-1. J Clin Endocrinol Metab 1990;71:1632–6.
Jacob R, Barrett E, Plewe G, Fagin KD, Sherwin RS. Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat: comparison with insulin. J Clin Invest 1989;83:1717–23.
Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor I on glucose, lipid and amino acid metabolism. Am J Physiol 1992;25:E130–3.
Rennert NJ, Caprio S, Sherwin RS. Insulin-like growth factor 1 inhibits glucose stimulated insulin secretion but does not impair glucose metabolism in normal humans. J Clin Endocrinol Metab 1993;76:804–6.
Kerr D, Tamborlane WV, Rife F, Sherwin RS. Effect of insulin-like growth factor I on the response to and recognition of hypoglycemia in humans: a comparison with insulin. J Clin Invest 1993;91:141–7.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this paper
Cite this paper
Sherwin, R.S., Borg, W.P., Boulware, S.D. (1995). Metabolic Effects of IGF-I: Implications for the Therapy of Diabetes Mellitus. In: Blackman, M.R., Roth, J., Harman, S.M., Shapiro, J.R. (eds) GHRH, GH, and IGF-I. Serono Symposia USA. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-0807-5_18
Download citation
DOI: https://doi.org/10.1007/978-1-4612-0807-5_18
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-6908-3
Online ISBN: 978-1-4612-0807-5
eBook Packages: Springer Book Archive